Multiple sclerosis (MS) is an immune-mediated inflammatory disease of the 
central nervous system considered the second cause of disability in young 
adults. The prognosis of MS has improved significantly since the approval of the 
first interferon β in 1993 but, compared to other diseases, few new therapeutic 
products have been commercialized in the last years. However, currently, there 
are more than 600 ongoing clinical trials and new drugs that aim to improve 
efficacy and a more convenient schedule of administration, will appear shortly 
on the market. On the other hand, new safety issues will arise as well as a 
significant economic impact on the health system. The main efficacy and safety 
results of these drugs are reviewed in this paper. They can be classified into 2 
groups: oral (fingolimod, laquinimod, teriflunomide, BG-12 [dimethyl fumarate], 
oral cladribine, dalfampridine) and monoclonal antibodies (rituximab, 
ocrelizumab, ofatumumab, daclizumab, alemtuzumab).